Crodex10%

Crodex is a topical scabicidal and antipruritic agent with two established uses:

• Treatment of scabies caused by Sarcoptes scabiei in adults and older children — an FDA-approved indication.
• Symptomatic relief of pruritus (itching) from various causes, including itching that persists after scabies has been treated, and itching due to eczema, dry skin, sunburn, insect bites, or other minor dermatologic irritation — an approved, well-established use.

Crodex is generally regarded as somewhat less consistently effective than permethrin for scabies eradication according to comparative data, and its use for scabies is guided by specific clinical circumstances, local treatment guidelines, and product availability. It is sometimes combined with permethrin in fixed-dose topical products marketed in some countries, including Bangladesh.

Each unit of Crotamiton topical preparation (cream or lotion) typically contains Crotamiton 10% w/w as the active ingredient, along with a cream or lotion base of excipients such as emulsifying agents, stabilizers, and preservatives. Some combination products contain Crotamiton together with permethrin; strengths and combinations vary by manufacturer and market.

Crodex (N-ethyl-o-crotonotoluidide) is a topical scabicidal and antipruritic agent applied directly to the skin. It is used both to kill the mite responsible for scabies and to relieve itching from a variety of dermatologic causes. Crodex is available as a cream or lotion, typically at a 10% concentration, for external use only.

The precise mechanism by which Crodex kills scabies mites is not fully established, though it is believed to have direct scabicidal activity. Its antipruritic effect is thought to relate to a mild counter-irritant and cooling action on the skin that reduces the perception of itch.

Crodex belongs to the therapeutic class of topical scabicides and antipruritics — agents applied to the skin to eradicate the scabies mite and/or relieve itching.

Crotamiton exerts a direct scabicidal (mite-killing) action against Sarcoptes scabiei when applied topically, although its exact molecular mechanism of action has not been fully elucidated in the scientific literature.

Separately, Crotamiton provides symptomatic relief of pruritus through a mild counter-irritant and evaporative cooling effect on the skin, which is thought to help distract from and reduce the sensation of itching, rather than through a specific antihistaminic or anti-inflammatory mechanism.

Crotamiton is applied topically and is minimally absorbed systemically when used as directed on intact skin; it is not intended for oral or systemic use.

Crodex is for external (topical) use only and must not be swallowed, and must not be applied to the eyes, mouth, lips, urethral meatus, vagina, or other mucous membranes. Wash hands thoroughly after application unless the hands themselves are being treated. Avoid application to acutely inflamed, raw, or weeping skin.

No clinically significant drug-drug interactions are well established for topically applied Crodex, since systemic absorption through intact skin is minimal when used as directed. Concurrent use of other topical irritant or drying agents on the same skin area may increase local skin irritation. Patients should inform their physician of all topical and systemic medicines they are using before starting Crodex.

Crodex is generally well tolerated when applied as directed. Reported adverse effects include:

• Local skin irritation (mild burning, stinging, or redness)
• Contact dermatitis or allergic skin reaction
• Pruritus (itching) at the application site, which may occasionally worsen rather than improve
• Rash

If severe irritation, sensitization, or an allergic reaction develops, discontinue use of Crodex and consult a physician.

Crodex has not been well studied in pregnant women, and there is limited data establishing its safety during pregnancy. It should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; use during the first trimester is generally best avoided unless specifically advised by a physician. It is not known whether topically applied Crodex is excreted in human breast milk; as a precaution, breastfeeding mothers should avoid applying Crodex to the breast/nipple area and should consult a physician before use. In all cases, use of Crodex during pregnancy or lactation should be under medical supervision.

Crodex is for external use only. Observe the following precautions:

• Avoid contact with the eyes, mouth, and other mucous membranes; if accidental contact occurs, rinse thoroughly with water.
• Do not apply to acutely inflamed skin or to raw or weeping surfaces.
• Discontinue use and consult a physician if signs of sensitization, worsening irritation, or an allergic reaction occur (see Side Effects).
• For scabies treatment, apply to the entire body from the neck down as directed, not only to visibly affected patches, and treat household/close contacts simultaneously as advised, to prevent reinfection.
• If symptoms of scabies or pruritus do not improve after the recommended course of treatment, consult a physician rather than continuing to reapply indefinitely.
• Keep out of reach of children; use in young children only under medical supervision (see Use in Special Populations).

Crodex is intended for external use only. Accidental ingestion or extensive/prolonged overapplication may increase the risk of systemic absorption and toxicity. If accidental ingestion occurs, or if excessive skin irritation, allergic reaction, or any other concerning symptoms develop after use, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment. Do not use more Crodex, or more often, than directed.

Store at room temperature (below 30°C), away from light and moisture. Keep the container tightly closed and out of reach of children.

Elderly: No dose adjustment is generally required; use as directed for adults, with attention to skin fragility.

Renal/Hepatic impairment: Specific dose adjustment data are not well established, as systemic absorption is minimal with topical use; use with routine caution.

Pediatric patients: See Pediatric Uses.

Pregnancy and lactation: See Pregnancy and Lactation above for detailed guidance.

For scabies, treatment with Crodex typically involves an application followed by a repeat application approximately 24 hours later, with a cleansing bath about 48 hours after the final application — a course usually lasting up to 3–5 days as directed by the treating physician. Itching may persist for several weeks after successful mite eradication and does not necessarily indicate treatment failure. For general pruritus, Crodex may be used as needed for symptomatic relief, but if symptoms persist beyond about one to two weeks, a physician should be consulted to reassess the diagnosis and treatment plan.

Topical scabicide; topical antipruritic (anti-itch) agent.

Crotamiton acts locally on the skin as a direct scabicidal agent against Sarcoptes scabiei, though its precise molecular mechanism has not been fully characterized. Its antipruritic action is thought to arise from a mild counter-irritant and cooling effect at the site of application, which helps reduce the sensation of itch, rather than from a specific pharmacologic (e.g., antihistaminic) pathway.

The safety and efficacy of Crodex in infants and very young children have not been fully established. In children under 3 years of age, Crodex should be used only under direct medical supervision, with application typically limited to once daily if used at all, due to the potential for greater relative systemic absorption through thinner, more permeable infant skin and the resulting risk of irritation or toxicity. In older children, Crodex is used similarly to adult dosing for both scabies and pruritus, under a physician's guidance. Parents/caregivers should avoid application to the child's hands if the child is likely to put hands in the mouth, and should avoid the face and mucous membranes at all times.